| TRADING CENTER |
| StemCells, Inc. CEO Martin McGlynn Featured On BioBusiness.TV's “Stem Cell Rev... - Business Wire | |
| StemCells, Inc. Initiates Landmark Trial Targeting “Communication Highway” of the... - Business Wire | |
| StemCells, Inc. Provides Update on NCL Program Meeting with FDA - Business Wire | |
| Trading Outlook for StemCells Inc. Issued by InvestorSoup.com - GlobeNewswire | |
| StemCells, Inc. Reports Third Quarter Financial Results - Business Wire | |
| StemCells, Inc. Closes $12.5 Million Equity Financing - Business Wire | |
| Integrity Media: Stem Cell Report Released - GlobeNewswire | |
| StemCells, Inc. Announces $12.5 Million Equity Financing - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.08 | 0.28 / 0.49% | 10.91 |
| GILD | Gilead Sciences Inc | 46.98 | 0.02 / 0.04% | 18.14 |
| CELG | Celgene Corporation | 55.75 | 0.38 / 0.69% | 67.17 |
| 2008 Revenue: | $232,000.0 | Headquarters: Palo Alto, CA |
| Employees: | 55 | CEO: Martin M. McGlynn |
| Net Income: | $-29,087,000.0 | Industry: Biotechnology |
| Market Cap: | $129.0 M | Website: www.stemcellsinc.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| STEM | 1.09 | -0.02 / -1.80% | 1.11 | 1.12 | 1.08 | Profile Chart News |